Regulatory Counsel

0910-AI45 201910 The Regulatory Plan and the Unified Agenda of Federal Regulatory and Deregulatory Actions 0910 Food and Drug Administration FDA 0900 Department of Health and Human Services HHS Importation of Prescription Drugs

This proposed rule, if finalized, would allow importation of certain drugs under certain circumstances. Pharmacists and wholesalers would be allowed to import prescription drugs from Canada into the United States if they meet conditions designed to ensure that the importation poses no additional risk to safety and will achieve cost savings.

]]> Other Significant First Time Published in The Unified Agenda Proposed Rule Stage Undetermined Undetermined Deregulatory Not Yet Determined Not Yet Determined Yes

Currently, prescription drugs can cost more in the United States than they do in Canada. This proposed rulemaking would rely on the authority in Federal Food, Drug, and Cosmetic Act (FD&C Act) section 804 to authorize importation of drugs from Canada under conditions that meet statutory criteria for safety and cost considerations. The proposed rule would include conditions and other elements to ensure the importation poses no additional risk to the public’s health and safety and that it will achieve significant cost savings to the American consumer.

]]>

The legal basis for this proposed rule is FD&C Act section 804.

]]>

Section 804 provides the statutory framework for allowing importation of prescription drugs from Canada, and it sets forth specific conditions to which HHS must certify in order to use this authority. Based on careful evaluation, FDA and HHS have not identified any alternative approaches to implementing section 804 that would meet the statutory certification criteria.

]]>

The proposed rule would create costs associated with the conditions and elements required or authorized by statute to ensure that implementation poses no additional safety risks and generates cost savings, including costs to government associated with the implementation and monitoring of any activities authorized under these regulations. Benefits from the proposed rule would be in the form of cost savings to consumers, which depend on the scope and scale of activities authorized under these regulations.

]]> ]]> NPRM 01/00/2020 Undetermined Businesses Undetermined Undetermined No Yes Kate Greenwood Regulatory Counsel 0910 Food and Drug Administration FDA 204 402-1748 kate.greenwood@fda.hhs.gov 10903 New Hampshire Avenue, Building 51, Room 6286, Silver Spring MD 20993